Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, starting with Hong Kong.</li>
<li>This list has been compiled on a best effort basis from tracking the company filings and through various other sources.</li>
<li>The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.</li>
</ul>


In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, starting with Hong Kong.
This list has been compiled on a best effort basis from tracking the company filings and through various other sources.
The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.


Aequitas 2026 Asia IPO Pipeline - Hong Kong

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>Whether WeiMai’s business model can operate sustainably and effectively depends on whether it can establish long-term/stable relationship with hospitals/doctors, as they are the key stakeholders to attract/retain the downstream customers.</li>
<li>However, the relationship between WeiMai and the hospital network may not be solid, thereby shaking the foundation of the entire business model. Gross margin level is unsatisfactory compared with peers.</li>
<li>Post-Money valuation after Series D+ Financing was US$559 million. Due to the concerns on business model and the profitability, WeiMai’s valuation should be lower than <a href="https://www.smartkarma.com/entities/ping-an-healthcare-and-technology-company-limited" target="_blank" data-smartkarma-citation="entities:27008:1" rel="noopener">Ping An Healthcare and Technology</a>.</li>
</ul>


Whether WeiMai’s business model can operate sustainably and effectively depends on whether it can establish long-term/stable relationship with hospitals/doctors, as they are the key stakeholders to attract/retain the downstream customers.
However, the relationship between WeiMai and the hospital network may not be solid, thereby shaking the foundation of the entire business model. Gross margin level is unsatisfactory compared with peers.
Post-Money valuation after Series D+ Financing was US$559 million. Due to the concerns on business model and the profitability, WeiMai’s valuation should be lower than Ping An Healthcare and Technology.


Pre-IPO WeiMai - The Pain Points Behind the Business Model

WeDoctor Holdings / Equity Capital Markets

<ul>
<li>We Doctor's business structure has undergone significant changes. Its positioning has become the AI-enabled healthcare solutions provider. The current business model of We Doctor is To G (To Government) model.</li>
<li>Whether We Doctor can replicate Tianjin model in other cities is uncertain because it may not have deep connections/resources in new cities/regions. Profit model of AI+ healthcare isn’t yet clear.</li>
<li>We Doctor's Pre-IPO valuation has reached US$6.7 billion, which is too expensive. Reasonable valuation could be just US$1-2 billion, and should be lower than Ping An Good Doctor.</li>
</ul>


We Doctor's business structure has undergone significant changes. Its positioning has become the AI-enabled healthcare solutions provider. The current business model of We Doctor is To G (To Government) model.
Whether We Doctor can replicate Tianjin model in other cities is uncertain because it may not have deep connections/resources in new cities/regions. Profit model of AI+ healthcare isn’t yet clear.
We Doctor's Pre-IPO valuation has reached US$6.7 billion, which is too expensive. Reasonable valuation could be just US$1-2 billion, and should be lower than Ping An Good Doctor.


Pre-IPO We Doctor Holdings - The Good Story of AI May Not Turn Things Around

Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

<ul>
<li>According to PHIP and Crunchbase, We Doctor’s most recently reported valuation was a ~$411M Series F led by HongShan Capital and Millennium Management at a ~$6.7B post-money valuation.  </li>
<li>My ballpark estimates suggest that IPO valuation target may be below last round valuation. However, I do not expect a significant discount to Series F post-money valuation of ~$6.7B.</li>
<li>I think investors will ask what is the revenue growth trajectory ahead (FY25-FY28) and why gross profit margins can’t be higher? What is the path to positive free cash flow?</li>
</ul>


According to PHIP and Crunchbase, We Doctor’s most recently reported valuation was a ~$411M Series F led by HongShan Capital and Millennium Management at a ~$6.7B post-money valuation.  
My ballpark estimates suggest that IPO valuation target may be below last round valuation. However, I do not expect a significant discount to Series F post-money valuation of ~$6.7B.
I think investors will ask what is the revenue growth trajectory ahead (FY25-FY28) and why gross profit margins can’t be higher? What is the path to positive free cash flow?


We Doctor Holdings IPO: Some Thoughts on IPO Valuation Target Ahead of the Offering

<ul>
<li>We Doctor Holdings, a top-tier provider of AI-enabled medical services and digital platform which connects hospitals, doctors, and pharmacies, plans to go public in Hong Kong.</li>
<li>We Doctor Holdings has raised ~$1.5B to date from investors, including Tencent, 5Y Capital, Goldman Sachs, Hillhouse Capital, AIA, and Qiming Venture Partners, among others.</li>
<li>The Hangzhou-based healthtech company has delivered explosive revenue growth of 107% y/y for the six months ended Jun-24.  </li>
</ul>


We Doctor Holdings, a top-tier provider of AI-enabled medical services and digital platform which connects hospitals, doctors, and pharmacies, plans to go public in Hong Kong.
We Doctor Holdings has raised ~$1.5B to date from investors, including Tencent, 5Y Capital, Goldman Sachs, Hillhouse Capital, AIA, and Qiming Venture Partners, among others.
The Hangzhou-based healthtech company has delivered explosive revenue growth of 107% y/y for the six months ended Jun-24.  


We Doctor Holdings IPO Preview: Explosive Growth and Narrowing Losses, The Right Time for an IPO

China

Wedoctor Group operates health care software businesses. The Company provides registration, medical advice, and other services. Wedoctor Group conducts business in China. 

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

WeDoctor Holdings (1737089D HK)

Aequitas 2026 Asia IPO Pipeline - Hong Kong

In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, starting with Hong Kong before covering other regions in subsequent...

Sumeet Singh

Pre-IPO WeiMai - The Pain Points Behind the Business Model

WeiMai's sustainability hinges on building strong relationships with hospitals and doctors, but shaky ties may impact business model.Profit margin...

Xinyao (Criss) Wang

Pre-IPO We Doctor Holdings - The Good Story of AI May Not Turn Things Around

We Doctor shifts to AI medical solution provider with To G model, facing uncertainty in replicating Tianjin model nationwide.Pre-IPO valuation at...

Xinyao (Criss) Wang

We Doctor Holdings IPO: Some Thoughts on IPO Valuation Target Ahead of the Offering

In my insight, I discuss expectations from upcoming We Doctor Holdings IPO and provide some thoughts on IPO valuation target ahead of the offering...

Andrei Zakharov

We Doctor Holdings IPO Preview: Explosive Growth and Narrowing Losses, The Right Time for an IPO

We Doctor, a Tencent-backed online healthcare platform and provider of AI-enabled medical services in China, has refiled PHIP to proceed with up to...

Andrei Zakharov

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Aequitas 2026 Asia IPO Pipeline - Hong Kong

In this note, we will take a look at the Asia Pacific IPO pipeline for 2026, starting with Hong Kong before covering other regions in subsequent...

Sumeet Singh

Pre-IPO WeiMai - The Pain Points Behind the Business Model

​WeiMai's sustainability hinges on building strong relationships with hospitals and doctors, but shaky ties may impact business model.Profit margin...

Xinyao (Criss) Wang

Pre-IPO We Doctor Holdings - The Good Story of AI May Not Turn Things Around

​We Doctor shifts to AI medical solution provider with To G model, facing uncertainty in replicating Tianjin model nationwide.Pre-IPO valuation at...

Xinyao (Criss) Wang

We Doctor Holdings IPO: Some Thoughts on IPO Valuation Target Ahead of the Offering

In my insight, I discuss expectations from upcoming We Doctor Holdings IPO and provide some thoughts on IPO valuation target ahead of the offering...

Andrei Zakharov

We Doctor Holdings IPO Preview: Explosive Growth and Narrowing Losses, The Right Time for an IPO

We Doctor, a Tencent-backed online healthcare platform and provider of AI-enabled medical services in China, has refiled PHIP to proceed with up to...

Andrei Zakharov

WeiMai's sustainability hinges on building strong relationships with hospitals and doctors, but shaky ties may impact business model.Profit margin...

We Doctor shifts to AI medical solution provider with To G model, facing uncertainty in replicating Tianjin model nationwide.Pre-IPO valuation at...